GenMont Biotech Incorporation (3164.TW)
TWD 19.15
(-0.78%)
TWD 19.15
(-0.78%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.65 Billion TWD | -2.51% |
| 2022 | 1.69 Billion TWD | -0.13% |
| 2021 | 1.69 Billion TWD | 5.28% |
| 2020 | 1.61 Billion TWD | 2.65% |
| 2019 | 1.57 Billion TWD | -5.26% |
| 2018 | 1.65 Billion TWD | 10.54% |
| 2017 | 1.5 Billion TWD | 6.87% |
| 2016 | 1.4 Billion TWD | -14.08% |
| 2015 | 1.63 Billion TWD | -6.21% |
| 2014 | 1.74 Billion TWD | 26.81% |
| 2013 | 1.37 Billion TWD | -13.02% |
| 2012 | 1.57 Billion TWD | 5.81% |
| 2011 | 1.49 Billion TWD | 9.32% |
| 2010 | 1.36 Billion TWD | 88.58% |
| 2009 | 724.09 Million TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.72 Billion TWD | 4.16% |
| 2024 Q2 | 1.72 Billion TWD | -0.06% |
| 2023 Q4 | 1.65 Billion TWD | 0.73% |
| 2023 FY | 1.65 Billion TWD | -2.51% |
| 2023 Q2 | 1.63 Billion TWD | -3.49% |
| 2023 Q3 | 1.64 Billion TWD | 0.28% |
| 2023 Q1 | 1.69 Billion TWD | -0.0% |
| 2022 Q1 | 1.73 Billion TWD | 2.47% |
| 2022 Q2 | 1.69 Billion TWD | -2.73% |
| 2022 FY | 1.69 Billion TWD | -0.13% |
| 2022 Q4 | 1.69 Billion TWD | 2.11% |
| 2022 Q3 | 1.66 Billion TWD | -1.88% |
| 2021 FY | 1.69 Billion TWD | 5.28% |
| 2021 Q1 | 1.64 Billion TWD | 2.03% |
| 2021 Q2 | 1.65 Billion TWD | 0.65% |
| 2021 Q3 | 1.6 Billion TWD | -3.2% |
| 2021 Q4 | 1.69 Billion TWD | 5.91% |
| 2020 Q2 | 1.53 Billion TWD | -2.93% |
| 2020 Q3 | 1.57 Billion TWD | 3.18% |
| 2020 Q4 | 1.61 Billion TWD | 2.14% |
| 2020 Q1 | 1.57 Billion TWD | 0.34% |
| 2020 FY | 1.61 Billion TWD | 2.65% |
| 2019 Q1 | 1.74 Billion TWD | 5.25% |
| 2019 Q3 | 1.64 Billion TWD | -6.38% |
| 2019 Q4 | 1.57 Billion TWD | -4.47% |
| 2019 FY | 1.57 Billion TWD | -5.26% |
| 2019 Q2 | 1.75 Billion TWD | 0.67% |
| 2018 Q2 | 1.59 Billion TWD | 4.79% |
| 2018 Q4 | 1.65 Billion TWD | 1.77% |
| 2018 FY | 1.65 Billion TWD | 10.54% |
| 2018 Q1 | 1.52 Billion TWD | 1.45% |
| 2018 Q3 | 1.62 Billion TWD | 2.17% |
| 2017 Q2 | 1.46 Billion TWD | 5.53% |
| 2017 FY | 1.5 Billion TWD | 6.87% |
| 2017 Q4 | 1.5 Billion TWD | -0.19% |
| 2017 Q3 | 1.5 Billion TWD | 2.35% |
| 2017 Q1 | 1.39 Billion TWD | -0.87% |
| 2016 Q1 | 1.61 Billion TWD | -1.24% |
| 2016 Q2 | 1.61 Billion TWD | -0.01% |
| 2016 Q3 | 1.61 Billion TWD | 0.34% |
| 2016 Q4 | 1.4 Billion TWD | -13.29% |
| 2016 FY | 1.4 Billion TWD | -14.08% |
| 2015 Q1 | 1.7 Billion TWD | -2.38% |
| 2015 Q3 | 1.69 Billion TWD | 2.2% |
| 2015 Q2 | 1.65 Billion TWD | -2.52% |
| 2015 FY | 1.63 Billion TWD | -6.21% |
| 2015 Q4 | 1.63 Billion TWD | -3.56% |
| 2014 Q4 | 1.74 Billion TWD | -17.86% |
| 2014 FY | 1.74 Billion TWD | 26.81% |
| 2014 Q2 | 2.16 Billion TWD | -10.72% |
| 2014 Q3 | 2.12 Billion TWD | -2.06% |
| 2014 Q1 | 2.42 Billion TWD | 76.54% |
| 2013 Q2 | 1.39 Billion TWD | -14.74% |
| 2013 Q3 | 1.37 Billion TWD | -1.66% |
| 2013 Q4 | 1.37 Billion TWD | 0.27% |
| 2013 FY | 1.37 Billion TWD | -13.02% |
| 2013 Q1 | 1.63 Billion TWD | 3.46% |
| 2012 Q4 | 1.57 Billion TWD | -1.6% |
| 2012 Q3 | 1.6 Billion TWD | 10.13% |
| 2012 Q2 | 1.45 Billion TWD | -1.55% |
| 2012 Q1 | 1.48 Billion TWD | -0.83% |
| 2012 FY | 1.57 Billion TWD | 5.81% |
| 2011 Q1 | 1.58 Billion TWD | 16.41% |
| 2011 Q2 | 1.57 Billion TWD | -0.75% |
| 2011 Q3 | 1.5 Billion TWD | -4.88% |
| 2011 Q4 | 1.49 Billion TWD | -0.52% |
| 2011 FY | 1.49 Billion TWD | 9.32% |
| 2010 FY | 1.36 Billion TWD | 88.58% |
| 2010 Q4 | 1.36 Billion TWD | 0.0% |
| 2009 FY | 724.09 Million TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Apex Biotechnology Corp. | 2.29 Billion TWD | 28.029% |
| Sinphar Pharmaceutical Co.,Ltd. | 6.25 Billion TWD | 73.554% |
| Panion & Bf Biotech Inc. | 3.23 Billion TWD | 48.9% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 5.17 Billion TWD | 68.034% |
| Abnova (Taiwan) Corporation | 1.35 Billion TWD | -21.939% |
| Adimmune Corporation | 9.48 Billion TWD | 82.57% |
| Tanvex BioPharma, Inc. | 2.76 Billion TWD | 40.176% |
| Polaris Group | 9.09 Billion TWD | 81.829% |
| Energenesis Biomedical CO.,LTD. | 828.57 Million TWD | -99.522% |
| UnicoCell Biomed Co., Ltd. | 685.92 Million TWD | -141.013% |
| PELL Bio-Med Technology Co. Ltd. | 1.41 Billion TWD | -16.573% |